<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181030041503N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-02-16</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Clinical pregnancy rate in transfer of  fresh embryo ,  5 days vs 3 days</public_title>
      <acronym></acronym>
      <scientific_title>Clinical trial comparing pregnancy rate in transfer of blastocyst vs cleavage stage in assisted reproductive technology</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>220</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35152</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The random  list is using the PASS software.The type of randomization is simple . The analyst and doctor will be unaware of the intervention and control groups, Blinding description: The researcher does not know how to randomize .The Embryologist chooses patients according to random numbers in each group.Patient and evaluator of the results are not known from the assigned group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Transfer of fresh embryo in assisted reproductive technology.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group:Three ovarian stimulation protocols( long protocol , microdoze and antagonist protocol ) were used to prepare patients for ivf depending on their age and diagnosis. Final oocyte maturation was induced by administration of 10 000 IU hCG when at least three follicles   with a diameter of 17 mm were observed during pelvic ultrasound. Oocyte retrieval was performed by vaginal ultrasound-guided puncture 36 h after hCG administration. . Oocytes incubated in IVF medium at 37 °C with  6 %CO2 and 5 % O2 in air with saturated humidity.  Finally Oocytes were fertilized by either insemination (IVF) or ICSI. Embryos were cultured in sequential media . The women will be randomly divided into two groups A fresh transfer was performed either on Day 3 or on day 5 after pick up.The luteal phase was supported by utrogestan Vaginal 600 mg daily. Intervention 2: Control group: Three ovarian stimulation protocols( long protocol , microdoze and antagonist protocol ) were used to prepare patients for ivf depending on their age and diagnosis. Final oocyte maturation was induced by administration of 10 000 IU hCG when at least three follicles with a diameter of 17 mm were observed during pelvic ultrasound. Oocyte retrieval was performed by vaginal ultrasound-guided puncture 36 h after hCG administration.  Oocytes incubated in IVF medium at 37 °C with 6%CO2 and 5 % O2 in air with saturated humidity. Then surrounding cumulus oophorus and corona radiata cells removed for intracytoplasmic sperm injection (ICSI). Finally Oocytes were fertilized by either insemination (IVF) or ICSI. embryos were cultured in sequential media . The women will be randomly divided into two groups .A fresh transfer was performed either on Day 3 or on day 5 after pick up.The luteal phase was supported by utrogestan vaginal( utrogestan,Besins,Brussels,Belgium ) 600 mg daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is I am reviewing the subject</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Malihe Mahmoudinia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Milad Fertility Clinic, East Razi Street, Dah e Day Square,</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9178631973</zip>
        <telephone>+98 51 3853 4021</telephone>
        <email>MahmoudiniaM@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nayyereh khadem</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Reza Hospital, Ebne Sina Street</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9178631973</zip>
        <telephone>+98 51 3801 2607</telephone>
        <email>khademn@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Uterine with normal cavity
Normal res ponder to ovarian stimulation
There are at least 5 fresh embryo
Sufficient thickness of endometrium in day 12 cycles</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>lack of embryo with good quality
Endocrine disorder(Hypothyroidism ,diabetes)
Poor respond er(less and equal 3 oocyte)
Excessive responder to ovarian stimulation (more than 20oocyte)
Freeze all of all embryos
Refusal to cooperation in the study
previous surgery of uterine
Recurrent  abortion
Sever male factor</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N98.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complications of attempted introduction of embryo in embryo transfer</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:Three ovarian stimulation protocols( long protocol , microdoze and antagonist protocol ) were used to prepare patients for ivf depending on their age and diagnosis. Final oocyte maturation was induced by administration of 10 000 IU hCG when at least three follicles   with a diameter of 17 mm were observed during pelvic ultrasound. Oocyte retrieval was performed by vaginal ultrasound-guided puncture 36 h after hCG administration. . Oocytes incubated in IVF medium at 37 °C with  6 %CO2 and 5 % O2 in air with saturated humidity.  Finally Oocytes were fertilized by either insemination (IVF) or ICSI. Embryos were cultured in sequential media . The women will be randomly divided into two groups A fresh transfer was performed either on Day 3 or on day 5 after pick up.The luteal phase was supported by utrogestan Vaginal 600 mg daily.</i_keyword>
      <i_keyword>Control group: Three ovarian stimulation protocols( long protocol , microdoze and antagonist protocol ) were used to prepare patients for ivf depending on their age and diagnosis. Final oocyte maturation was induced by administration of 10 000 IU hCG when at least three follicles with a diameter of 17 mm were observed during pelvic ultrasound. Oocyte retrieval was performed by vaginal ultrasound-guided puncture 36 h after hCG administration.  Oocytes incubated in IVF medium at 37 °C with 6%CO2 and 5 % O2 in air with saturated humidity. Then surrounding cumulus oophorus and corona radiata cells removed for intracytoplasmic sperm injection (ICSI). Finally Oocytes were fertilized by either insemination (IVF) or ICSI. embryos were cultured in sequential media . The women will be randomly divided into two groups .A fresh transfer was performed either on Day 3 or on day 5 after pick up.The luteal phase was supported by utrogestan vaginal( utrogestan,Besins,Brussels,Belgium ) 600 mg daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Clinical pregnancy rate. Timepoint: 6 weeks after  embryo  transfer. Method of measurement: sonography.</prim_outcome>
      <prim_outcome>Chemical pregnancy rate. Timepoint: 2weeks after embryo transfer. Method of measurement: βHCG test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Ongoing pregnancy. Timepoint: Continued pregnancy up to 12 weeks. Method of measurement: Trans vaginal Sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-25</approval_date>
        <contact_name>Mashhad university of Medical sciences Ethics committee</contact_name>
        <contact_address>Mashhad University of Medical Sciences, Mashhad University of Medical Sciences,University Avenue, Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
